AC Immune Presents New Preliminary Data From Phase 1 Trial Of TDP-43 Positron Emission Tomography Tracer ACI-19626 Showing Increased Uptake In Brains Of Patients With Amyotrophic Lateral Sclerosis
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
AC Immune Q1 EPS $(0.19) Beats $(0.20) Estimate, Sales $1.429M Beat $1.000M Estimate
AC Immune Announces It Dosed The First Patients In Cohort AD4 In The Ongoing Phase 1b/2 ABATE Trial
AC Immune FY 2025 Results: Eyeing ACI-7104 Catalysts
AC Immune shares are trading higher after BTIG reiterated its Buy rating on the stock and maintained a $8 price target.
AC Immune Q4 EPS $(0.17) Beats $(0.19) Estimate, Sales $422.914K
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
AC Immune Doses First Participant In Phase 1 Study Of ACI-19764 Targeting Neuroinflammation In Alzheimer's, Parkinson's And ALS
Retail investors are AC Immune SA's (NASDAQ:ACIU) biggest owners and were rewarded after market cap rose by US$53m last week
Startup Lifordi Seeks to Deliver Potent Medication for Autoimmune Diseases
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's
AC Immune posts positive data for Parkinson’s immunotherapy
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
AC Immune shares are trading higher after the company announced interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein active immunotherapy ACI-7104.056 in early Parkinson's disease.
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
AC Immune Announces Interim Safety And Efficacy Results From Phase 2 VacSYn Trial Of Its Wholly-Owned Anti-Alpha-Synuclein Active Immunotherapy ACI-7104.056 In Early Parkinson's Disease
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.